PegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares

Bulletin Express04-09

PegBio Co., Ltd. announced that it has obtained a filing notice from the China Securities Regulatory Commission (CSRC) dated 26 March 2026, confirming completion of filing for its H Share full-circulation plan.

The approval covers the conversion of 101.70 million unlisted domestic shares into H Shares. PegBio must complete the share conversion within 12 months of the filing date or submit updated materials to the CSRC if it intends to proceed beyond that period.

Following conversion, the company will apply to The Stock Exchange of Hong Kong Limited for listing and permission to deal in the newly issued H Shares on the Main Board.

Management stated that detailed implementation arrangements are still being finalized. Further disclosures will be made in accordance with Hong Kong Listing Rules and Inside Information provisions.

The H Share full-circulation process remains subject to subsequent procedures required by the CSRC, HKEX and other regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in PegBio’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186046639?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 18:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186046639","market":"us","top_or_hot":-1,"title":"PegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares","media":"Bulletin Express","content":"<p>PegBio Co., Ltd. announced that it has obtained a filing notice from the China Securities Regulatory Commission (CSRC) dated 26 March 2026, confirming completion of filing for its H Share full-circulation plan.</p>\n<p>The approval covers the conversion of 101.70 million unlisted domestic shares into H Shares. PegBio must complete the share conversion within 12 months of the filing date or submit updated materials to the CSRC if it intends to proceed beyond that period.</p>\n<p>Following conversion, the company will apply to The Stock Exchange of Hong Kong Limited for listing and permission to deal in the newly issued H Shares on the Main Board.</p>\n<p>Management stated that detailed implementation arrangements are still being finalized. Further disclosures will be made in accordance with Hong Kong Listing Rules and Inside Information provisions.</p>\n<p>The H Share full-circulation process remains subject to subsequent procedures required by the CSRC, HKEX and other regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in PegBio’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-09 18:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PegBio Co., Ltd. announced that it has obtained a filing notice from the China Securities Regulatory Commission (CSRC) dated 26 March 2026, confirming completion of filing for its H Share full-circulation plan.</p>\n<p>The approval covers the conversion of 101.70 million unlisted domestic shares into H Shares. PegBio must complete the share conversion within 12 months of the filing date or submit updated materials to the CSRC if it intends to proceed beyond that period.</p>\n<p>Following conversion, the company will apply to The Stock Exchange of Hong Kong Limited for listing and permission to deal in the newly issued H Shares on the Main Board.</p>\n<p>Management stated that detailed implementation arrangements are still being finalized. Further disclosures will be made in accordance with Hong Kong Listing Rules and Inside Information provisions.</p>\n<p>The H Share full-circulation process remains subject to subsequent procedures required by the CSRC, HKEX and other regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in PegBio’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1186046639","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186046639","pubTimestamp":1775731664,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"PegBio Co., Ltd. announced that it has obtained a filing notice from the China Securities Regulatory Commission (CSRC) dated 26 March 2026, confirming completion of filing for its H Share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"培格生物收到证监会备案通知，将1.017亿股非上市股份转换为H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co., Ltd. announced that it has obtained a filing notice from the China Securities Regulatory Commission (CSRC) dated 26 March 2026, confirming completion of filing for its H Share full-circulation plan.\nThe approval covers the conversion of 101.70 million unlisted domestic shares into H Shares. PegBio must complete the share conversion within 12 months of the filing date or submit updated materials to the CSRC if it intends to proceed beyond that period.\nFollowing conversion, the company will apply to The Stock Exchange of Hong Kong Limited for listing and permission to deal in the newly issued H Shares on the Main Board.\nManagement stated that detailed implementation arrangements are still being finalized. Further disclosures will be made in accordance with Hong Kong Listing Rules and Inside Information provisions.\nThe H Share full-circulation process remains subject to subsequent procedures required by the CSRC, HKEX and other regulatory authorities. Shareholders and potential investors are advised to exercise caution when dealing in PegBio’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186046639","isCrawlerRequest":true}